Close
Achema middle east
swop processing & packaging

WHO Authorizes PAXLOVID, The First Oral COVID-19 Generic

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

The generic version of the COVID-19 oral antiviral therapy candidate nirmatrelvir has been approved by the World Health Organization Prequalification of Medicines Program (WHO PQ), as stated by the Indian pharmaceutical company Hetero.

This is the first prequalification for a generic form of PAXLOVID, an oral antiviral medicine manufactured by Pfizer and designated by the WHO as the best therapeutic option available for high-risk patients. Nirmatrelvir and ritonavir were strongly advised by the WHO for mild and moderate COVID-19 patients who were at the greatest risk of being admitted to the hospital, such as those who were immunosuppressed, elderly, or hadn’t had a vaccine.

Nirmatrelvir 150 mg (2 pills) and ritonavir 100 mg are both included in the combo pack, which Hetero is marketing as NIRMACOM (1 tablet). Only by prescription, it must be started within five days after the onset of symptoms and as soon as COVID-19 has been diagnosed. The production of NIRMACOM will take place at Hetero’s facilities in India.

In order to produce and market a generic version of Pfizer’s COVID-19 oral antiviral therapy candidate, nirmatrelvir, in low- and middle-income nations, Hetero engaged in a non-exclusive voluntary licencing agreement with Medicines Patent Pool.

Latest stories

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »